Estradiol diundecylate/hydroxyprogesterone heptanoate/testosterone cyclohexylpropionate
Estradiol diundecylate/hydroxyprogesterone heptanoate/testosterone cyclohexylpropionate (EDU/OHPH/TCHP), sold under the brand name Trioestrine Retard, is an injectable combination medication of estradiol diundecylate (EDU), an estrogen, hydroxyprogesterone heptanoate (OHPH), a progestogen, and testosterone cyclohexylpropionate (TCHP), an androgen/anabolic steroid. It contained 2.25 mg EDU, 100 mg OHPH, and 67.5 mg TCHP in oil solution, was provided as ampoules, and was administered by intramuscular injection. The medication was manufactured by Roussel and Théramex and was marketed by 1953. It is no longer available.
| Combination of | |
|---|---|
| Estradiol diundecylate | Estrogen |
| Hydroxyprogesterone heptanoate | Progestogen |
| Testosterone cyclohexylpropionate | Androgen; Anabolic steroid |
| Clinical data | |
| Trade names | Trioestrine Retard |
| Other names | EDU/OHPH/TCHP |
| Routes of administration | Intramuscular injection |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.